← Back to Clinical Trials
Recruiting NCT00700414

NCT00700414 International Pediatric Adrenocortical Tumor Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00700414
Status Recruiting
Phase
Sponsor St. Jude Children's Research Hospital
Condition Adrenocortical Tumor
Study Type OBSERVATIONAL
Enrollment 9,999 participants
Start Date 2001-10-01
Primary Completion 2040-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 21 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 9,999 participants in total. It began in 2001-10-01 with a primary completion date of 2040-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to collect demographic and medical information including detailed family history of cancer of children and adolescents with adrenocortical tumors in order to learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients with this rare disease, worldwide. In addition, investigators at St. Jude Children's Research Hospital (SJCRH) plan to perform molecular studies of tumor cells aimed to clarify the role of the TP53 gene and other genetic pathways in these tumors. They aim to obtain relevant biological material from participants with adrenocortical tumor (ACT), their biological parents, and relatives for determination of the TP53 germline status, molecular studies of the TP53 gene, and other molecular pathways.

Eligibility Criteria

STRATIFICATION ASSIGNMENT: * Stratum A: participant suspected or confirmed diagnosis of adrenocortical tumor (ACT) * Stratum R: relative of participant with ACT and TP53 mutation who has diagnosis of malignancy * Stratum P: biological parent of participant with ACT Inclusion Criteria - Stratum A (participant with ACT): * Age ≤ 21 years old at diagnosis * Suspected or confirmed diagnosis of adrenocortical tumor (adenoma, carcinoma or undefined histology). * Signed informed consent Inclusion Criteria - Stratum R (relative): * Any age * Diagnosis of malignant tumor * Signed informed consent Inclusion Criteria - Stratum P (parent): * Biological parent of Stratum A participant

Contact & Investigator

Central Contact

Raul C Ribeiro, MD

✉ referralinfo@stjude.org

📞 866-278-5833

Principal Investigator

Raul C Ribeiro, MD

PRINCIPAL INVESTIGATOR

St. Jude Children's Research Hospital

Frequently Asked Questions

Who can join the NCT00700414 clinical trial?

This trial is open to participants of all sexes, up to 21 Years, studying Adrenocortical Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00700414 currently recruiting?

Yes, NCT00700414 is actively recruiting participants. Contact the research team at referralinfo@stjude.org for enrollment information.

Where is the NCT00700414 trial being conducted?

This trial is being conducted at Stanford, United States, St. Petersburg, United States, Dayton, United States, Memphis, United States and 1 additional location.

Who is sponsoring the NCT00700414 clinical trial?

NCT00700414 is sponsored by St. Jude Children's Research Hospital. The principal investigator is Raul C Ribeiro, MD at St. Jude Children's Research Hospital. The trial plans to enroll 9,999 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology